Drug Profile
Interferon beta-intranasal - Nastech Pharmaceutical Company
Latest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Nastech Pharmaceutical Company
- Class Antineoplastics; Antivirals; Interferons; Skin disorder therapies
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 25 May 2006 No development reported - Phase-I for Multiple sclerosis in USA (Intranasal)
- 07 May 2002 Phase-I clinical trials in Multiple sclerosis in USA (Intranasal)